Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | See Remarks | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,938 |
Last balance in matching sequence
After 2026-10-02 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2026-10-01 · Exercise / conversion · Acquired 413 · Balance 10,351 F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 2 · 2026-10-01 · Sale · Disposed 413 · Balance 9,938 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.30 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 3 · 2026-10-02 · Exercise / conversion · Acquired 24,587 · Balance 34,525 F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 4 · 2026-10-02 · Sale · Disposed 15,843 · Balance 18,682 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.38 to $116.36 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 5 · 2026-10-02 · Sale · Disposed 8,744 · Balance 9,938 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.39 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2027-02-10 | Direct | 66,573 |
Reported balance
After 2026-10-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-10-01 · Exercise / conversion · Disposed 413 · Balance 66,573 F11: Fully exercisable. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2027-02-10 | Direct | 41,986 |
Reported balance
After 2026-10-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-10-02 · Exercise / conversion · Disposed 24,587 · Balance 41,986 F11: Fully exercisable. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,147 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,147 F6: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 20,570 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 20,570 F7: Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 40,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 40,000 F8: Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 34,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 34,000 F9: Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 10,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 10,000 F10: Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.30 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.38 to $116.36 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.39 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F7: Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
F8: Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F9: Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F10: Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F11: Fully exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2025 Filed Jun 5, 2025 00:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 888 | $71.68 | $63,651.84 |
DisclosureSEC source: 0000950170-25-081933 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,817 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 2, 2025. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 29, 2025 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · derivative · entry 25 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 29, 2025 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 23 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 89,693 F2 · kind: Transfer of shares without consideration to the Sean and Molly Maduck Living Trust. F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| May 29, 2025 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 22 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,929 F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 29, 2025 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 10,000 | $3.88 | $38,800.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 21 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 02, 2025 Filed May 6, 2025 00:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 26,554 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0000950170-25-063835 · ownership.xml · derivative · entry 9 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,986 Underlying: Common Stock · 26,554 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 02, 2025 Filed May 6, 2025 00:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 707 | $72.98 | $51,596.01 |
DisclosureSEC source: 0000950170-25-063835 · ownership.xml · nonDerivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,622 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $72.95 to $73.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 02, 2025 Filed May 6, 2025 00:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 25,847 | $72.21 | $1,866,355.01 |
DisclosureSEC source: 0000950170-25-063835 · ownership.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,329 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $71.88 to $72.82 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 02, 2025 Filed May 6, 2025 00:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 26,554 | $5.05 | $134,097.70 |
DisclosureSEC source: 0000950170-25-063835 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 01, 2025 Filed May 6, 2025 00:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 12,856 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0000950170-25-063835 · ownership.xml · derivative · entry 8 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,540 Underlying: Common Stock · 12,856 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 01, 2025 Filed May 6, 2025 00:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 12,856 | $71.94 | $924,818.22 |
DisclosureSEC source: 0000950170-25-063835 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,622 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $71.88 to $72.10 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 01, 2025 Filed May 6, 2025 00:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 12,856 | $5.05 | $64,922.80 |
DisclosureSEC source: 0000950170-25-063835 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 590 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0000950170-25-049816 · ownership.xml · derivative · entry 10 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,396 Underlying: Common Stock · 590 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully exercisable. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 590 | $114.55 | $67,584.09 |
DisclosureSEC source: 0000950170-25-049816 · ownership.xml · nonDerivative · entry 6 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,622 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F6 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.29 to $114.71 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 590 | $5.05 | $2,979.50 |
DisclosureSEC source: 0000950170-25-049816 · ownership.xml · nonDerivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0000950170-25-049816 · ownership.xml · derivative · entry 9 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 100,000 shares Expires 2027-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,590 | $102.16 | $571,077.75 |
DisclosureSEC source: 0000950170-25-049816 · ownership.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,622 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $102.00 to $102.5250 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 15,133 | $101.43 | $1,534,937.16 |
DisclosureSEC source: 0000950170-25-049816 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,212 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $101.00 to $101.95 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 79,277 | $100.26 | $7,947,994.91 |
DisclosureSEC source: 0000950170-25-049816 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,345 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $100.00 to $100.97 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 100,000 | $8.27 | $827,000.00 |
DisclosureSEC source: 0000950170-25-049816 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 21:07 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 1,697 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0000950170-25-045431 · ownership.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,986 Underlying: Common Stock · 1,697 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 21:07 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 1,697 | $60.58 | $102,804.26 |
DisclosureSEC source: 0000950170-25-045431 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,622 F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 21:07 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 1,697 | $5.05 | $8,569.85 |
DisclosureSEC source: 0000950170-25-045431 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 18,303 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0000950170-25-032789 · ownership.xml · derivative · entry 9 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,683 Underlying: Common Stock · 18,303 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 18,303 | $60.69 | $1,110,818.22 |
DisclosureSEC source: 0000950170-25-032789 · ownership.xml · nonDerivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,622 F7 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. F8 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $60.58 to $61.055 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 18,303 | $5.05 | $92,430.15 |
DisclosureSEC source: 0000950170-25-032789 · ownership.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 266 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032789 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,622 F6 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 266 | $59.07 | $15,712.62 |
DisclosureSEC source: 0000950170-25-032789 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,356 F4 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 3, 2025. F5 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 228 | $60.58 | $13,812.24 |
DisclosureSEC source: 0000950170-25-032789 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,090 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · price: The closing price on February 28, 2025 was used to calculate the withholding obligation. F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 140,000 | $0.00 Strike: $60.58 | $0.00 |
DisclosureSEC source: 0000950170-25-032789 · ownership.xml · derivative · entry 8 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2035-02-28 F11 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:07 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 8,014 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0000950170-25-014463 · ownership.xml · derivative · entry 7 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,986 Underlying: Common Stock · 8,014 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:07 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 11,986 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0000950170-25-014463 · ownership.xml · derivative · entry 6 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 11,986 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:07 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 20,000 | $66.92 | $1,338,400.00 |
DisclosureSEC source: 0000950170-25-014463 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,318 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:07 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 8,014 | $5.05 | $40,470.70 |
DisclosureSEC source: 0000950170-25-014463 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:07 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 11,986 | $3.88 | $46,505.68 |
DisclosureSEC source: 0000950170-25-014463 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0000950170-25-002466 · ownership.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,986 Underlying: Common Stock · 20,000 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 20,000 | $50.39 | $1,007,800.00 |
DisclosureSEC source: 0000950170-25-002466 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,318 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $3.88 | $77,600.00 |
DisclosureSEC source: 0000950170-25-002466 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 00:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 265 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-133444 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,318 F6 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024 and 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 00:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 265 | $59.21 | $15,690.65 |
DisclosureSEC source: 0000950170-24-133444 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,053 F4 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 2, 2024. F5 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024 and 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 00:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 295 | $57.68 | $17,015.60 |
DisclosureSEC source: 0000950170-24-133444 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,788 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · price: The closing price on November 29, 2024 was used to calculate the withholding obligation. F3 · balance_after: Includes 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024 and 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 03, 2024 Filed Sep 6, 2024 00:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 458 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-104199 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,083 F6 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 03, 2024 Filed Sep 6, 2024 00:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 458 | $34.26 | $15,691.08 |
DisclosureSEC source: 0000950170-24-104199 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,625 F4 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 3, 2024. F5 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 03, 2024 Filed Sep 6, 2024 00:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 232 | $35.30 | $8,189.60 |
DisclosureSEC source: 0000950170-24-104199 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,167 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · price: The closing price on August 30, 2024 was used to calculate the withholding obligation. F3 · balance_after: Includes 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 01:13 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 823 | $30.17 | $24,829.91 |
DisclosureSEC source: 0000950170-24-069604 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,399 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · price: The closing price on May 31, 2024 was used to calculate the withholding obligation. F3 · balance_after: Includes 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 13, 2024 Filed May 16, 2024 00:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0000950170-24-060767 · ownership.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,986 Underlying: Common Stock · 50,000 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 13, 2024 Filed May 16, 2024 00:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 50,000 | $28.00 | $1,400,000.00 |
DisclosureSEC source: 0000950170-24-060767 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,222 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 13, 2024 Filed May 16, 2024 00:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 50,000 | $3.88 | $194,000.00 |
DisclosureSEC source: 0000950170-24-060767 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 18:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 25,953 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0000950170-24-038530 · ownership.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,986 Underlying: Common Stock · 25,953 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 18:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 25,953 | $25.01 | $649,024.84 |
DisclosureSEC source: 0000950170-24-038530 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,222 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.